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Lauren Bolcar Comment- Second Draft 
PATENTING THE HUMAN BODY: MYRIAD, PROMETHEUS, AND THE FUTURE OF PATENT ABLE 
SUBJECT MATTER IN THE UNITED STATES 
I. INTRODUCTION 
In 1990, the U.S. Human Genome Project officially began efforts to map the entire 
human genome. 1 The international project lasted thirteen years and cost approximately $2.7 
billion.2 In addition to gaining valuable insight about the human genetic code, researchers are 
working to develop disease diagnostic tests and treatments using Deoxyribonucleic Acid (DNA) 
analysis. 3 Diagnostic testing for genetic disorders has increased steadily over the past two 
decades.4 Over 350 biotechnology products are currently in clinical trials; many of these are 
based on genetic research.5 A 2005 study found that nearly 20% of human genes are explicitly 
claimed in U.S. patents.6 Many of these patents cover genes associated with numerous diseases, 
such as Alzheimer's disease, 7 cystic fibrosis, 8 Canavan disease,9 and asthma.1 0 
Researchers seek patents for gene sequences in order to provide incentives that are 
critical to downstream investment, which will, in turn, lead to further discoveries on which 
1 U.S. Dep't. ofEnergy Office of Sci., About the Human Genome Project, Genomics.engergy.gov., 
http://www.ornl.gov/sciltechresources/Human_ Genome/projectJabout.shtml (last updated Sept. 19, 2011). 
2 See Nat'l Human Genome Research Inst., Nat' I Institutes of Health, The Human Genome Project Completion: 
Frequently Asked Questions, http://www.genome.gov/11006943 (last updated Oct. 30, 2010). 
3 /d. ("Individualized analysis based on each person's genome will lead to a very powerful form of preventive 
medicine .... Then, through our understanding at the molecular level of how things like diabetes or heart disease or 
schizophrenia come about, we should see a whole new generation of interventions, many of which will be drugs that 
are much more effective and precise than those available today."). 
4 Gert Matthijs & Gert-Jan B. Van Ommen, Gene Patents: From Discovery to Invention. A Geneticist's View, in 
GENE PATENTS AND COLLABORATIVE LICENSING MODELS: PATENT POOLS, CLEARINGHOUSES, OPEN SOURCE 
MODELS AND LIABILITY REGil\IIES 311, 316 (Geertrui Van Overwalle ed., Cambridge University Press 2009). 
5 Jd 
6 Gloria Bevan & Kyle Jensen, Intellectual Property Landscape of the Human Genome, 310 SCI., 239-40,239 
(2005). 
7 Ronald Kotulak, Taking License With Your Genes: Biotech Firms Say They Need More Protection, CHI. TRIB., 
Sept. 12, 1999, http:/ /articles.chicagotribune.com/1999-09-12/news/9909120225 _1_gene-patents-patent-office-
molecular-pathology-laboratory. 
8 Id 
9 Arthur Allen, Who Owns My Disease?, 26 MOTHER JONES 52-59 (2001). 
_ --~--------1~ U.S._Patent No_,_6,_Q37,14_9 ([Iled_Mar.J4, 2000), _ -~---- __ _ 
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genetic tests are based. 11 In the pharmaceutical and diagnostic healthcare industry, patent 
protection is viewed as crucial in aiding the recouping of substantial costs associated with the 
discovery and development of new therapies. 12 Patent-holders claim that without patent 
protection, there would be little motivation to make the discoveries in the first place, or to 
publish them.13 The corporation Myriad Genetics has argued that if gene patents are no longer 
allowed, future developments in genetic diagnostic testing and therapies will slow or cease, or 
will not be disclosed in order to maintain trade-secret protection.14 
There is a great deal of controversy surrounding gene patents.15 Famous author Michael 
Crichton expressed the fears of many researchers, doctors, and patients when he wrote the 
following in a New York Times opinion editorial: "[y]ou, or someone you love, may die because 
of a gene patent that shouid never have been granted in the first piace. Sound far-fetched? 
Unfortunately, it's only too real."16 A 2005 survey of laboratory directors in the United States 
sought to quantify the impact of gene patents on the ability of doctors to perform research and 
provide clinical genetic testing services.17 The study found that 53% of respondents decided not 
to develop or perform a test or service for clinical or research purposes because of a patent, 18 and 
11 Beyan & Jensen, supra note 6; Mildred K. Cho et al., Effects of Patents and Licenses on the Provision of Clinical 
Genetic Testing Services, 5 J. MOLECULAR DIAGNOSTICS 3,4 (2003), 
http://www .ncbi.nlm.nih.gov/pmc/articles/PMC 19073 68/pdf/0 1 08.pdf. 
12 Cho, supra note 11 at 3 ein this industry particularly, patents are seen as necessary to enhance an inventor's 
ability to recoup the substantial investments of many ears and hundreds of millions of dollars necessary to bring a 
new drug or device to market."); Ass'n for Molecular Pathology v. U.S. Patent and Trademark Office, 702 
F.Supp.2d 181,210-11 (S.D.N.Y. 2010). 
13 Kotula.~7 supra note 7. 
14 Brief for Appellant at 4 Ass'n for Molecular Pathology v. U.S. Patent and Trademark Office, 653 F.3d 1329, 1350 
(Fed. Cir. 2011) (No. 2010-1406). 
15 Jordan Paradise, European Opposition to Exclusive Control over Predictive Breast Cancer Testing and the 
Inherent Implications for U.S. Patent Law and Public Policy: A Case Study of the Myriad Genetics' BRCA Patent 
Controversy, 59 FOOD & DRUG L.J. 133, 133 (2004). 
16 Michael Crichton, Patenting Life, N.Y. TIMES, Feb. 13,2007, http://www.nytimes.com/2007/02/13/opinion/ 
13 crichton.html. 
17 Cho, supra note 11, at 3. 
18 Jd at 5. 
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67% reported a decreased ability to conduct research. 19 The American Society of Human 
Genetics found similar results in a separate survey, where 46% of respondents felt that patents 
had limited or delayed their research. 20 
Along with gene patents, diagnostic method patents have been the source of recent 
controversy.21 Since 2006 three cases involving diagnostic method patents have reached the 
Supreme Court of the United States22 with the potential for another case in the near future.23 
These cases are similar in that the diagnostic method patent in question involves a transformative 
or quantitative element originating within the human body: amino acid levels in a patient's 
blood,24 drug metabolite concentrations,25 patent immunization on a determined schedule,26 or 
cancer cell growth rates in the presence of potential therapeutics. 27 
This Comment will discuss the judicial precedent surrounding diagnostic method claims 
utilizing scientific breakthroughs in genetic research, with an emphasis on the recent and 
publicized Association for Molecular Pathology v. US. Patent and Trademark Office 
("Myriad'').Z8 It will argue that under current patent law, Myriad was correctly decided, yet due 
to critical public policy concerns, the time may have arrived for a reinterpretation of what is 
considered patent-eligible subject matter. Part II is a brief overview what is considered 
19 Jd. at 7. 
20 Ass'n for Molecular Pathology v. U.S. Patent and Trademark Office, 702 F.Supp.2d 181,208 (S.D.N.Y. 2010). 
21 Asher Hodes, Note, Diagnosing Patentable Subject Matter, 26 BERKELEY TECH. L.J. 225, 230. 
22 Lab. Corp. of America Holdings v. Metabolite Laboratories, Inc., 548 U.S. 124, 125 (2006) (dismissing writ of 
certiorari as improvidently granted); Prometheus Laboratories, Inc. v. Mayo Collaborative Services, 581 F.3d 1336 
(Fed. Cir. 2009), vacated, 130 S.Ct. 3543 (2010), rev'd, 628 F.3d 1347 (Fed. Cir. 2010), cert. granted, 131 S.Ct. 
3027 (U.S. Jun 20, 2011) (No. 10-1150); Classen Immunotherapies, Inc. v. Biogen IDEC, 130 S.Ct. 3541 (2010) 
(vacating judgment and remanding for further consideration in light of Bilski v. Kappos, 130 S.Ct. 3218 (2010)), 
aff din part, rev' din part, vacated in part, 659 F .3d 1057 (Fed. Cir. 2011 ). 
23 Hodes, supra note 21 at 225; Ass'n for Molecular Pathology v. U.S. Patent and Trademark Office, 653 F.3d 1329 
(Fed. Cir. 2011),petitionfor cert.filed. 
24 Metabolite Laboratories, Inc., 548 U.S. 125 (2006). 
25 Prometheus, 581 F.3d at 1347. 
26 Classen Immunotherapies, Inc. v. Biogen IDEC, 659 F.3d 1057 (Fed. Cir. 2011). 
27 Ass'n for Molecular Pathology v. U.S. Patent and Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011). 
28ld 
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patentable under U.S. patent law. Parts III and IV discuss the patentability of DNA and method 
claims, respectively. Part Vis dedicated to a study of the Myriad case, which represents the 
intersection of diagnostic method patents and gene patenting. Part VI analyzes the impact of the 
Myriad decision and the future of diagnostic method patenting. 
II. UNITED STATES PATENT LAW-PATENT ELIGIBLE Sl.JBJECT MATTER 
A United States patent confers upon the patentee an exclusive right to the patented 
invention for twenty years after the date the patent application was filed with the United States 
Patent and Trademark Office (USPT0)?9 In exchange for this right to exclude, the inventor 
must publicly disclose the invention through the specification. 30 In order to be patent eligible, 
the invention must meet several statutory requirements: it must concern patent-eligible subject 
matter,31 it must be novel,32 and it must be non-obvious?3 
Patent-eligible subject matter is defined by Section 101 of the Patent Act of 1952 as: "any 
new and useful process, machine, manufacture, or composition of matter, or any new and useful 
improvement thereof .... "34 Under Section lOO(b) of the Patent Act, "[t]he term 'process' 
29 35 U.S.C. § 154(a)(2) (2011). The patent grants the patent holder ~'the right to exclude others from making, using, 
offering for sale, or selling the invention throughout the United States or importing the invention into the United 
States, a.11d, !fthe fu.yention is a process, of the right to exclude other-:; from using) offering for sale or selling 
throughout the United States, or importing into the United States, products made by that process .... " 35 U.S.C. § 
154 (a)(l) (2011). 
30 35 U.S.C § 112 (2011). "The specification shall contain a written description of the invention, and of the manner 
and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the 
art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the 
best mode contemplated by the inventor of carrying out his invention. The specification shall conclude with one or 
more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his 
invention." The first and second paragraphs of §112 (aoove) provide the distinct disclosure requirements for patent 
protection. This written information is collectively known as the patent specification. Accord F. SCOTTKEFF ET 
AL., PRINCIPLES OF PATENT LAW: CASES AND MATERIALS 154-55 (Robert C. Clark et al. eds., 5th ed. 2011). 
31 35 u.s.c. § 101 (2011). 
32 35 u.s.c. § 102 (2011). 
33 35 U.S.C. § 103(a) (2011). "A patent may not be obtained though the invention is not identically disclosed or 
described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented 
and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was 
made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be 
negatived by the manner in which the invention was made." 
34 35 U.S.C. § 101 (2011). 
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means process, art or method, and includes a new use of a known process, machine, 
manufacture, composition of matter, or materia1."35 The Supreme Court has interpreted the 
definition of patent-eligible subject matter as describing "four independent categories of 
inventions or discoveries that are eligible for protection: processes, machines, manufactures, and 
compositions ofmatter."36 The Court has also recognized that Congress intended that the scope 
of patentable subject matter should be given a broad interpretation.37 Indeed, one may describe 
patent-eligible subject matter as "includ[ing] anything under the sun that is made by man."38 
There are limitations, however, to what may be considered patent-eligible subject matter. 
Supreme Court precedent "provides three specific exceptions to § 101 's broad patent-eligibility 
principles: 'laws of nature, physical phenomena, and abstract ideas. "'39 As the number of 
patents covering pioneering technologies increases, the courts have struggled to develop a clear 
framework for determining patent eligibility under § 1 01, especially when the claimed invention 
does not produce tangible results, or when public policy concerns call for limiting patentability.40 
III. PATENT ABILITY OF DNA 
The 1980 Supreme Court case Diamond v. Chakrabarty41 held that a live, man-made 
microorganism was patentable under§ 101 as a "manufacture" or "composition ofmatter.',42 
This proved to be a seminal decision on patentable subject matter, as thousands of patents 
relating to genes and genetic material have been awarded since this case was decided.43 In 1983, 
35 35 U.S.C. § IOO(b) (2011). 
36 Bilski v. Kappos, 130 S. Ct. 3218,3225 (2010). 
37 Diamond v. Chakrabarty, 447 U.S. 303, 308 (1980) ("In choosing such expansive terms ... modified by the 
comprehensive 'any,' Congress plainly contemplated that the patent laws would be given wide scope."). 
38 ld at 309 (quoting the language of the Congressional Committee Reports accompanying the 1952 Patent Act). 
39 Bilski, 130 S. Ct. at 3225 (quoting Chakrabarty, 447 U.S. at 309). 
40 Stephen W. Chen, et al., Patent Protection in Medicine and Biotechnology: An Overview, 4 J. HEALTH & LIFE SCI. 
L. 106, 132 (2011). 
41 447 u.s. 303 (1980). 
42 Chakrabarty, 447 U.S. at 303. 
43 Jordan Paradise, European Opposition to F.xclusive f:nntrnl over Predictive Breast Cancer Testing and the 
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the USPTO expanded the scope of patent protection available for genetic material by issuing the 
first patents relating to "isolated DNA."44 In 1991, the CAFC held that claims for a "purified 
and isolated DNA sequence" were valid and enforceable. 45 The USPTO has adopted this policy 
regarding the patentability of isolated and purified DNA, acknowledging it as patent eligible 
because "(1) an excised gene ... does not occur i11 that isolated form in nature, or (2) ... their 
purified state is different from the naturally occurring compound."46 
The Supreme Court has not yet defmitively ruled on the patentability of DNA.47 The 
closest the Court has come to addressing this issue was in Laboratory Corp of America Holdings 
v. Metabolite Laboratories, Inc. ("LabCorp"). 48 Metabolite Laboratories was the licensee of a 
patent that claimed methods for detecting vitamin Band folic acid deficiencies in patients.49 
Metabolite sued LabCorp for patent infringement when LabCorp began using a similar test 
developed by another company and discontinued royalty payments to Metabolite. 5° Specifically, 
the disputed claim was for a method of "detecting vitamin B deficiencies by measuring amino 
acid levels in a patient's blood and then correlating those amino acid levels with vitamin B 
levels."51 LabCorp argued that this claim (claim 13 of Metabolite's patent) was invalid for a 
variety of reasons, 52 but did not raise the issue of invalidity under § 1 01 until their appeal to the 
Inherent Implications for US. Patent Law and Public Policy: A Case Study of the Myriad Genetics' BRCA Patent 
Controversy. 59 FOOD & DRUG L.J. 133, 133 (2004) ("Between 1980 and 2001, the U.S. Patent and Trademark 
Office (USPTO) awarded over 8,000 patents on genes and genetic material, including at least 1,500 claiming 
sequences of human genetic material."). 
44 See U.S. Patent No. 4,680,264 claim 27 (filed July 1, 1983) (claiming a recombinant vector rather than genomic 
DNA). 
45 Amgen Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1219 (Fed. Cir. 1991). 
46 USPTO Examination Guidelines http://www. uspto.gov/web/o:ffices/com/sollnotices/utilexmguide.pdf (200 1 ). 
47 Petition for Writ of Certiorari, Ass'nfor Molecular Pathology, 16 (2011). 
48 Lab. Corp. of America Holdings v. Metabolite Laboratories, Inc., 548 U.S. 124, 125 (2006) (Breyer, JJ., 
dissenting). 
49 Metabolite Laboratories, Inc. v. Lab. Corp. of America Holdings, 370 F.3d 1354, 1358-59 (Fed. Cir. 2004). 
50 Metabolite Laboratories, Inc., 370 F.3d at 1359. 
51 Hodes, supra note 21 at 230; accord U.S. Patent No. 4,940,658 (filed Nov. 20, 1986). 
52 Metabolite Laboratories, Inc., 370 F.3d at 1365 ("LabCorp argues that claim 13 is invalid on grounds of 
indefmiteness, lack of written description and enablement, anticipation, an~ obviousness."). 
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Supreme Court. 53 The Supreme Court initially granted certiorari, yet later dismissed it as 
improvidently granted, 54 perhaps because the lower courts had not yet had an opportunity to rule 
on that issue. Consequently, the CAFC holding that the disputed claim is valid55 and that 
LabCorp infringed the claim56 is still valid. 
IV. PATENT ABILITY OF METHOD CLAIMS 
The Supreme Court has held that a valid process claim cannot claim "laws of nature, 
natural phenomena, [or] abstract ideas."57 For example, an abstract mathematical formula 
cannot be patented. 58 The Court implemented these restrictions in order to discourage patentees 
from attempting to claim abstract subject matter by limiting the formula to a specific 
technology. 59 These restrictions exist in order to prevent preemption, wherein a patent bars all 
application of a fundamental principle. 60 
A. The Development and Application of the Machine-or-Transformation Test 
In Gottschalk v. Benson61 the Court recognized that the "[t]ransformation and reduction 
of an article 'to a different thing' is the clue to the patentability of a process claim that does not 
include particular machines."62 The Court of Appeals for the Federal Circuit (''CAFC") later 
53 Brief for the United States as Amicus Curiae at 15-19, Lab. Corp. of America Holdings v. Metabolite 
Laboratories, Inc., 548 U.S. 124 (2006) (No. 04-607), 2005 WL 3533248; see also Metabolite Laboratories, Inc., 
548 U.S. at 132 (''Question Three of the petition asks ' [ w ]hether a method patent ... directing a party simply to 
correlat[ e] test results can validly claim a monopoly over a basic scientific relationship ... such that any doctor 
necessarily infringes the patent merely by thinking about the relationship after looking at a test result.") (citation 
omitted). 
54 Metabolite Laboratories, Inc., 548 U.S. at 125-26. 
55 Metabolite Laboratories, Inc., 370 F.3d at 1368. 
56 Id at 1365. 
57 Diamond v. Diehr, 450 U.S. 175, 185 (1981). 
58 Gottschalk v. Benson, 409 U.S. 63,71 (1972). 
59 Diehr, 450 U.S. at 192-93 ("We view respondents' claims as nothing more than a process for molding rubber 
products and not as an attempt to patent a mathematical formula .... A mathematical formula as such is not 
accorded the protection of our patent laws ... and this principle cannot be circumvented by attempting to limit the 
use of the formula to a particular technological environment." (citations omitted)). 
60 Tiana Leia Russell, Unlocking the Genome: The Legal Case Against Genetic Diagnostic Patents, 16 MARQ. 
lNTELL. PROP. L. REV. 81, 91 (2012). 
61 409 U.S. 63 (1972). 
62 Rensnn, 409 l J.S. at 70. 
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cited this standard as "a definitive test" for determining patent eligibility of a process claim in In 
re Bilski.63 The Supreme Court held that the mathematical algorithm was not a "process" but an 
abstract idea and therefore unpatentable. 64 The Court explained that to hold otherwise "would 
wholly pre-empt the mathematical formula and in practical effect would be a patent on the 
algorithtn itself."65 
In Parker v. Flook, 66 the Court established "that limiting an abstract idea to one field of 
use or adding token postsolution components did not make the concept patentable."67 However, 
the Court explained in Diamond v. Diehr that claims containing mathematical formulas which 
are tied to a valid application of a natural phenomenon or abstract idea may be patentable as a 
whole. 68 Under Diehr, when a claim contains a fundamental principle (such as a mathematical 
tbrmula, natural phenomenon, or scientific principle), ~~an inquiry must be made into whether the 
claim is seeking patent protection for u~at formula i11 the abstract."69 In other words, although 
the entire claim must be considered when determining patentability, "the inventive concept 
cannot derive solely from the fundamental principle."70 
In Bilski v. Kappos71 the CAFC drew on Supreme Court case law to articulate a two-
prong "definitive test" for determining process patent eligibility. The court determined that "[a] 
63 In re Bilslti, 545 F.3d 943 (Fed. Cir. 2008) ("The Supreme Court, however, has enunciated a definitive test to 
determine whether a process claim is tailored narrowly enough to encompass only a particular application of a 
fundamental principle rather than to pre-empt the principle itself. A claimed process is surely patent-eligible under § 
101 if: (1) it is tied to a particular machine or apparatus, or (2) it transforms a particular article into a different state 
or thing."). 
64 Benson, 409 U .S.at 71. 
65 !d. at 72. 
66 437 u.s. 584 (1978). 
67 Bilski, 130 S. Ct. at 3231. 
68 Diehr, 450 U.S. at 192 ("[W]hen a claim containing a mathematical formula implements or applies that formula in 
a structure or process which, when considered as a whole, is performing a function which the patent laws were 
designed to protect (e. g., transforming or reducing an article to a different state or thing), then the claim satisfies the 
requirements of§ 101."). 
69 Id 450 U.S. at 191. 
70 Russell, supra note 60 at 81. 
71 130 S. Ct. 3218 (2010). 
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claimed process is surely patent-eligible under§ 101 if: (1) it is tied to a particular machine or 
apparatus, or (2) it transforms a particular article into a different state or thing."72 A patentee 
need only show the process claim satisfies one of the two prongs to patent-eligible.73 Following 
the analysis of Benson, Flook, and Diehr, the CAFC explained that "the use of a specific 
machine or transformation of an article must impose meaningful limits on the claim's scope to 
impart patent-eligibility," and "the involvement of the machine or transformation in the claimed 
process must not merely be insignificant extra-solution activity."74 Essentially, the purpose of 
the claimed process must be the transformation of the article.75 
The claimed invention at issue in Bilski v. Kappos involved a method of protecting 
buyers and sellers of commodities in the energy market against the risk of price changes. 76 The 
CAFC framed the issue as determining what "process" means as defined in § 101, and how to 
establish whether a particular claim is a "new and useful process."77 The CAFC concluded that 
the "machine-or-transformation test" was "the sole test for governing § 101 analyses"78 and thus 
was the "test for determining patent eligibility of a process under § 1 01. "79 Applying the 
machine-or-transformation test, the CAFC held the application at issue was not patentable as it 
satisfied neither the machine80 nor transformation81 prong of the test. 
The Supreme Court granted certiorari to clarify the proper use of the machine-or-
transformation test. According to the Court, the CAFC "incorrectly concluded that this Court 
72 In re Bilski, 545 F.3d 943, 953 (Fed. Cir. 2008). 
73 Id at 961. 
74 Id at 961-62 (citations omitted). 
75 Id at 962. 
76 Bilski, 130 S. Ct. at 3223 . 
.77 In re Bilski, 545 F.3d 943, 951 (Fed. Cir. 2008). 
78 ld. at 955. 
79 I d. at 956. 
80 Id at 962 e'As to machine implementation, Applicants themselves admit that the language of claim 1 does not 
limit any process step to any specific machine or apparatus."). 
81 I d. at 963 ("We hold that the Applicants' process as claimed does not transfonn any article to a different state or 
thing."). 
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has endorsed the machine-or-transformation test as the exclusive test."82 Rather, the Court 
categorized the test as "a useful and important clue, an investigative tool, for determining 
whether some claimed inventions are processes under§ 101."83 The Court explained that while 
the machine-or-transformation test may work well for determining patentability of physical or 
ta11gible inventions, it ¥/ould "create u..11certainty" as to the patentability of more complex subject 
matter. 84 The Court warned that too narrow a test might render newer and more nuanced 
technologies unpatentable.85 Interestingly, the CAFC recognized such an issue in its own 
analysis of the Bilski case, and predicted the Supreme Court expanding the patentability test in 
the future. 86 The Court ultimately affirmed the decision of the CAFC, holding the claims 
unpatentable as abstract ideas, yet the Court did so by confining its analysis to the principles 
established in Benson, Flook, and Diehr.81 Under these cases, to detennine if a patent is 
preemptive, ''the key consideration is whether the patent threatens to (a) v1holly preempt the 
fundamental principle or (b) be the only practical and useful application of the principle."88 
B. Patentability of Diagnostic Method Claims 
82 Bilski, 130 S. Ct. at 3226 (201 0). 
83 Id at 3227. 
84 Jd ("[T]he machine-or-transformation test would create uncertainty as to the patentability of software, advanced 
diagnostic medicine techniques, and inventions based on linear programming, data compression, and the 
manipulation of digital signals."). 
85 Jd ("In the course of applying the machine-or-transformation test to emerging technologies, courts may pose 
questions of such intricacy and refinement that they risk obscuring the larger object of securing patents for valuable 
inventions without transgressing the public domain."). 
86 In re Bilski, 545 F.3d at 956 ("[W]e agree that future developments in technology and the sciences may present 
difficult challenges to the machine-or-transformation test, just as the widespread use of computers and the advent of 
the Internet has begun to challenge it in the past decade. Thus, we recognize that the Supreme Court may ultimately 
decide to alter or perhaps even set aside this test to accommodate emerging technologies. And we certainly do not 
rule out the possibility that this court may in the future refme or augment the test or how it is applied. At present, 
however, and certainly for the present case, we see no need for such a departure and reaffirm that the machine-or-
transformation test, properly applied, is the governing test for determining patent eligibility of a process under § 
10 1."). 
87 Bilski, 130 S. Ct. at 3229-30 ("Rather than adopting categorical rules that might have wide-ranging and 
unforeseen impacts, the Court resolves this case narrowly on the basis of this Court's decisions in Benson, Flook, 
and Diehr, which show that petitioner's claims are not patentable processes because they are attempts to patent 
abstract ideas."). 
88 Russell, supra note 60 at 81. 
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There are three types of process patents typically related to the medical field: (1) medical 
procedures that do not require the use of any patented medical products, (2) methods for using a 
patented drug or device, and (3) techniques for isolating chemical compounds or building 
devices.89 In 2009, the CAFC upheld the validity of two method patents owned by Prometheus 
Laboratories, Inc. (Prometheus).90 The patents claim methods for optimizing the proper dosage 
of thiopurine drugs, which are used to treat both gastrointestinal and non-gastrointestinal 
autoimmune diseases. 91 The Prometheus patents involve a process for the measurement of two 
metabolites in order to "optimize therapeutic efficacy while minimizing toxic side effects."92 
The patents contain two separate steps: "administering" a drug ... to a patient, and 
"determining" the levels of drug metabolites ... in the patient. 93 The measured metabolite levels 
are then compared to a range of metabolite concentration contained in the claims, '"wherein' the 
measured metabolite levels 'indicate a need' to increase or decrease the level of drug to be 
administered so as to minimize toxicity and maximize efficacy of the treatment."94 
Prometheus marketed a test that used the technology described in the patents.95 In 2004 
Mayo Collaborative Services and Mayo Clinic Rochester (Mayo) announced it would be selling 
89 Margaret Kubick, Note, An Uncertain Future: The Impact of Medical Process and Diagnostic Method Patents on 
Healthcare in the United States, 9 Nw. J. TECH. & lNTELL. PROP. 280, 14, (2010). 
90 Prometheus Laboratories, Inc. v. Mayo Collaborative Services, 581 F.3d 1336 (Fed. Cir. 2009). 
91 Prometheus, 581 F.3d at 1339; U.S. Patent No. 6,355,623 (filed Apr. 8, 1999) (describing a ~'[m]ethod of treating 
IBD/Crobn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent 
dosage"); U.S. Patent No. 6,680,302 (filed Dec. 27, 2001) (describing "[m]ethods of optimizing drug therapeutic 
efficacy for treatment of immune-mediated gastrointestinal disorders"). 
92 Prometheus, 581 F.3d at 1339. 
93 Jd 
94 Jd (quoting language from the patents at issue. Claim 1 ofU.S. Patent No. 6,355,623 is representative of the 
claims asserted by Prometheus: "A method of optimizing therapeutic efficacy for treatment of an immune-medicated 
gastrointestinal disorder, comprising: (a) administering a drug providing 6-thioguanine to a subject having said 
immune-medicated gastrointestinal disorder; and (b) determining the level of 6-thioguanine in said subject having 
said immune-medicated gastrointestinal disorder, wherein the level of 6-thioguanine less than about 230 pmol per 
8x 108 red blood cells indicates a need to increase the amount of said drug subsequently administered to said subject 
and wherein the level of 6-thioguanine greater than about 400 pmol per Sx 1 08 red blood cells indicates a need to 
decrease the amount of said drug subsequently administered to said subject.") 
95 ld at 1340. 
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its own test, which measured the same metabolites as the Prometheus test, but used different 
metabolite levels to determine toxicity.96 Prometheus sued Mayo for patent in:fringement.97 The 
District Court for the Southern District of California granted Mayo's motion for summary 
judgment of invalidity under§ 101, finding that "the 'administering' and 'determining' steps are 
merely necessary data-gathering steps for any use of the correlations and that as constructed5 the 
fmal step ... is only a mental step."98 
On appeal the CAFC began its analysis by reviewing the machine-or-transformation test 
for process patent eligibility under § 101 it had recently utilized in the Bilski decision.99 It held 
that the method of treatment claims were patentable subject matter as it satisfied the 
transformation prong of the test. 100 The court reasoned that the transfonnative step in the process 
was when the body metabolized the administered drug.101 The fact that t1i.e change of the 
administered drug into Lherapeutic metabolites relied on natural process was not dispositive, for 
"quite literally every transformation of physical matter can be described as occurring according 
to natural processes and naturallaw."102 The CAFC likewise found the determining steps 
transformative, as the levels of metabolite could not be ascertained without some form of 
manipulation or modification of the bodily sample to determine the concentration of the 
metabolites therein. 103 The court then concluded that the "administering" and "determining" 
steps were essential to the claimed process, and therefore were not merely data-gathering or 
96 Jd 
97 Jd 
98 Prometheus, 581 F.3d at 1341 (internal quotations omitted). 
99 ld. at 1342-43. 
100 /d. at 1344. 
101 Jd at 1346 ("The drugs do not pass through the body untouched without affecting it. In fact, the transformation 
that occurs, viz., the effect on the body after metabolizing the artificially administered drugs, is the entire purpose of 
administering the drugs: the drugs are administered to provide 6-TG, which is thought to be the drugs' active 
metabolite in the treatment of the disease, to a subject."). 
102 Jd. 
103 Prometheus, 581 F.3d at 1347. 
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"insignificant extra-solution activity."104 The CAFC agreed with the district court that the 
"wherein" clauses of the claims were mental steps, but this did not render the entire process 
unpatentable. 105 The CAFC emphasized that the entire claimed process must be viewed as a 
whole.106 Finally, the CAFC disagreed with the fmding of the district court that the claims 
wholly preemptive of the correlations between metabolite levels and toxicity or efficacy.107 The 
CAFC returned to the machine-or-transformation test,108 and determined that "[t]he inventive 
nature of the claimed methods stems not from preemption of all use of these natural processes, 
but from the application of a natural phenomenon in a series of transformative steps comprising 
particular methods oftreatment."109 
Following the CAFC ruling the Supreme Court granted certiorari, vacated the judgment 
in light of its Bilski decision, and remanded the case back down to the CAFC for further 
consideration.110 On remand the CAFC requested briefs from both parties addressing the effect 
of the Bilski decision the case at bar. 111 
The second Prometheus opinion follows a similar line of reasoning to the frrst opinion, 
despite the additional guidance from the Bilski decision. The CAFC recognized that in light of 
Bilksi, the issue of patent eligibility turned on whether the Prometheus claims were drawn to a 
natural phenomenon, which would result in complete preemption if patented, or "whether the 
claims were drawn only to a particular application of that phenomenon, as in Die hr. "112 
According to the CAFC, the Bilski decision did not impose a "wholly different analysis or a 
104 ld at 1348. 
105 Jd ('~A subsequent mental step does not, but itself, negate the transformative nature of prior steps."). 
106 Jd at 1349. 
107 Jd. 
108 Prometheus. 581 F.3d at 1349("[B]ecause the claims meet the machine-or-transformation test, they do not 
preempt a fundamental principle."). 
109 ld. 
110 Prometheus, 130 S. Ct. 3543 (2010). 
111 Prometheus, F.3d at 1353. 
112 Id at 1354. 
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different result on remand."113 The Bilski decision served only to correct the CAFC's original 
presumption that the machine-or-transformation test was the exclusive test for process 
patentability.114 As a result, the CAFC once again held the diagnostic claims as patentable under 
§ 101, using much ofthe same analysis as in the original opinion. 115 
The Supreme Cou.rt again gr8.nted certiorari Ln June 2011, u 6 which seemingly indicates 
the CAFC misinterpreted the lesson of Bilski. On remand, Mayo argued that the Bilski decision 
"reaffirmed that preemption is the controlling standard for§ 101" under Supreme Court 
precedent, and ~'made clear that while a machine-or-transformation test may inform the analysis, 
the test is not outcome determinative."117 Mayo maintains that Prometheus's claims are invalid 
as preempting all practical use of a natural phenomenon, and that the claims satisfy the machine-
or-transfonuation test "is merely insigHifica.t"lt post-solution activity."118 
V. MYRIAD: iNTERSECTION OF DIAGNOSTIC METHOD PATENTS AND GENETIC TESTING 
The Myriad case is especially compelling because it is an amalgamation of diagnostic 
method and gene patents. Myriad Genetics held seven U.S. patents regarding two isolated 
human genes (BRCA1 and BRCA2), mutations of which were associated with a predisposition to 
breast and ovarian cancers. 119 The Myriad patents originated with an international research 
initiative focused on breast cancer research. Several European and American research 
laboratories founded the Breast Cancer Linkage Consortium (Consortium) in 1989 to promote 
the open exchange of data and ideas with the expressed goal of discovering the genetic basis of 
113 Jd at 1355. 
114 ld 
115 ld ("Thus, the Court did not disavow the machine-or-transformation test. And, as applied to the present claims, 
the 'useful and important clue, an investigative tool,' leads to a clear and compelling conclusion, viz., that the 
present claims pass muster under § I 0 I. They do not encompass laws of nature or preempt natural correlations."). 
116 Prometheus, 131 S. Ct. 3027. 
117 Prometheus, 628 F.3d at I354. 
ns Id 
119 Ass'nfor Molecular Pathology, 653 F.3d at 1334. 
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breast cancer.120 
In 1990 a team from the Consortium localized the BRCA1 gene. 121 A year later another 
member of the Consortium, Mark Skolnick from the University of Utah, founded Myriad 
Genetics in order to capitalize on the research once the complete gene was sequenced.122 Myriad 
successfully cloned and sequenced the BRACI gene in 1994.123 In the United Kingdom in 1994, 
the Institute of Cancer Research localized the BRAC2 gene.124 It was further characterized by 
Myriad.125 
Beginning in 1995, Myriad sought U.S. patent protection for the isolated BRCA1/2 genes 
as well as methods of diagnostic testing for the genetic mutations contained therein.126 The 
European Patent Office (EPO) granted Myriad and co-inventors several patents based on these 
genes. 127 The method claims patented by Myriad have been divided into two categories: method 
for "comparing" and "analyzing" DNA sequences, 128 and method for screening potential cancer 
therapeutics through changes in cell growth rates.129 The second type of claim is found in patent 
5,747,282 (the '282 patent) and is directed to "a method for identifying potential cancer 
therapeutics by utilizing cells into which an altered BRCA1 gene known to cause cancer has 
120 Paradise, supra note 15 at 143. 
121 Matthijs & Van Ommen, supra note 4 at 319; Paradise, supra note 81, at 143. 
122 Matthijs & Van Ommen, supra note 4 at 320. 
123 ld. 
124 ld. 
125 ld. 
126 U.S. Patent No. 5,747, 282 (filed June 7, 1995) (claimmg ''[a]n isolated DNA codmg for a BRCA 1 polypeptide . 
. . . " and "a method for screenmg potential cancer therapeutics" usmg "an BRCA 1 gene .... ");U.S. Patent No. 
5,837,492 (filed Apr. 29, 1996) (claimffig "[a]n isolated DNA molecule codmg for a BRCA2 polypeptide .... "); 
U.S. Patent No. 5,693,473 (filed June 7, 1995) (claiming "[a]n isolated DNA comprising an altered BRCAl DNA ... 
. "); U.S. Patent No. 5, 709,999 (filed June 7, 1995) ( claimffig "[a] method for detecting a germlffie alteration in a 
BRCA1 gene .... ''); U.S. Patent No. 5,710,001 (filed June 7, 1995) (claiming "[a] method for screening a tumor 
sample from a human subject for a somatic alteration in a BRCA1 gene in said tumor .... ");U.S. Patent No. 
5,753,441 (filed Jan. 5, 1996) (claiming "[a] method for screening germlffie of a human subject for an alteration of a 
BRCAI gene .... "); U.S. Patent No. 6,033,857 (filed Mar. 20, 1998) (claiming "A method for identi:fymg a mutant 
BRCA2 nucleotide sequence in a suspected mutant BRCA2 allele .... "). 
127 Matthijs & Van Ommen, supra note 4 at 320. 
128 Ass'nfor Molecular Pathology, 653 F.3d at 1355. 
129 ld at 1357. 
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been inserted."130 The growth rates of the artificial cancer cells are compared to determine the 
efficacy of a potential cancer therapeutic.131 
In 2009 the ACLU brought suit against Myriad Genetics on behalf of several medical 
organizations, researchers, genetic counselors, and patients to challenge the patentability of 
fifteen composition and method claims in U.S. patents relating to human genetics. i3l The ACLU 
charged that the Myriad patent claims were invalid as covering "products of nature, laws of 
nature and/or natural phenomena, and abstract ideas or basic human knowledge or thought."133 
The Southern District ofNew York held that the patents claiming at isolated DNA 
sequences, as well as the patents claiming comparisons of DNA sequences, were unpatentable 
under § 101.134 On appeal, the CAFC majority reversed the district court's holding that isolated 
Dl"~A is unpatentable w1der § 101.135 However, each member of the tt.uee-panel judge Wiote a 
separate opinion on this issue.136 While a great deal of the attention surrounding this case has 
been focused on the claims regarding the patentability of DNA, 137 due to the recent controversy 
generated by such patents, the CAFC's conclusions regarding the patentability of Myriad's 
130 Id at 1337; See also U.S. Patent No. 5,747, 282 (filed June 7, 1995) (claiming specifically ''A method for 
screening potential cancer therapeutics which comprises: growing a transformed eukaryotic host cell containing an 
altered BRCA1 gene causing cancer in the presence of a compound suspected ofbeing a cancer therapeutic, growing 
said transformed eukaryotic host cell in the absence of said compound, determining the rate of growth of said host 
cell in the presence of said compound and the rate of growth of said host cell in the absence of said compound and 
comparing the growth rate of said host cells, wherein a slower rate of growth of said host cell in the presence of said 
compound is indicative of a cancer therapeutic."). 
131 Ass 'n for Molecular Pathology, 702 F .Supp.2d at 237. 
132 Ass'nfor Molecular Pathology, 653 F.3d at 1333-34; Joshua D. Sarnoff, Patent Eligible Medical and 
Biotechnology Inventions after Bilski, Prometheus, and Myriad, 19 TEX. INT'LPROP. L.J. 393,408 (2011). 
133 Ass'nfor Molecular Pathology, 702 F.Supp.2d at 184. 
134 Id. at 185. 
135 Ass'nfor Molecular Pathology, 653 F.3 at 1350. 
136 See generally id at 1350 (concluding that claims relating to isolated DNA are patent~eligible subject matter under 
§ 101, regardless of limitation to eDNA or not); id. at 1361 (Moore, J., concurring-in-part) (emphasizing certain 
chemical considerations of particular importance); id at 1373 (Bryson, J., concurring-in-part and dissenting-in-part) 
(fmding isolated DNA claims not directed to patentable subject matter). 
137 E.g., Gene Quinn, As Predicted, Federal Circuit Rule Isolated DNA Patentable, IPWatchdog (July 29,2011,2:12 
PM), http:/ /ipwatchdog.com/20 11/07 /29/federal-circuit-rules-isolated-dna-patentable/id= 18487 /; Federal Circuit: 
Isolated Human DNA Molecules are Patentable, Patently-0 (July 29, 2011, 12:32 PM), 
http://www.patentlyo.com/patent/20 11/07 /federal-circuit-isolated-human-dna-molecules-are-patentable.html. 
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diagnostic method claims deserve attention as well. 138 
The CAFC affirmed the district court's ruling that the "comparing" and ''analyzing" 
claims were unpatentable under § 1 01.139 The CAFC found that the claims were drawn to ''the 
abstract mental process of comparing two nucleotide sequences" and declined to extend 
Myriad's claims to include the extraction and sequencing steps of DNA preparation prior to 
analysis.140 The CAFC distinguished its earlier Prometheus decision, which held that the claims 
at issue contained transformative steps as written, and the "determining" step of the claims "was 
both transformative and central to the purpose of the claims."141 In contrast, the CAFC found the 
Myriad claims did not include a determinative, gene sequencing step.142 The comparison 
between gene sequences could be accomplished by inspection alone. 143 
However, the CAFC disagreed with the district court regarding the patentability of the 
second type of method claim at issue (the '282 patent). Again the CAFC referenced its 
Prometheus decision when analyzing the Myriad claim.144 The court found that the claim 
included the transformative steps of: "(1) 'growing' host cells transformed with an altered 
BRCAl gene in the presence or absence of a potential cancer therapeutic, (2) 'determining' the 
growth rate of the host cell with or without the potential therapeutic, and (3) 'comparing' the 
growth rate of the host cells."145 These steps were found to be "central to the purpose of the 
138 Hodes, supra note 21 at 230. 
139 ld. at 1357. 
140 I d. (''The claims do not specify any action prior to the step of 'comparing' or 'analyzing' two sequences; the 
claims recite just the one step of 'comparing' or 'analyzing.' Moreover, those terms' plain meaning does not 
include Myriad's proposed sample-processing steps; neither comparing nor analyzing means or implies 'extracting' 
or 'sequencing' DNA or otherwise 'processing' a human sample."). 
141Jd. 
142 Ass'nfor Molecular Pathology, 653 F.3d at 1357. 
143 ld. 
144 ld. 
145 ld 
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claimed process."146 The court further determined that the claims were narrow enough to avoid 
preempting a natural phenomenon.147 This claim was held to concern patentable subject matter 
under § 101.148 
VI. IMPACT OF MYRIAD AND THE FUTURE OF GENETIC DIAGNOSTIC METHOD CLAIMS 
Since Prometheus was relied upon so heavily for both CAFC Myriad opinions, the 
forthcoming Supreme Court Prometheus ruling is likely to impact the Myriad line of cases and 
subsequent diagnostic patent cases. 149 It has been suggested that the Court's continued 
involvement in the Prometheus line of cases indicates that the machine-or-transformation test is 
not the appropriate method for determining patentability of diagnostic method claims.150 Some 
insight as to how the Supreme Court may analyze Prometheus can be found in the dissenting 
opinion of Justice Breyer in LabCorp.151 Justice Breyer, joined by Justices Stevens and Souter, 
dissented from the dismissal after cert had originally been granted. 152 In his opinion, Justice 
Breyer stated he would have held the disputed claim (methods for detecting vitamin B and folic 
acid deficiencies in patients) invalid as patenting a natural phenomenon. 153 According to Justice 
Breyer, the claimed process "is no more than an instruction to read some numbers in light of 
medical knowledge."154 As Justice Breyer's opinion is not a majority ruling, it has no binding 
146 Jd 
147 Jd at 1358 ("The claim does not cover all cells, all compounds, or all methods of determining the therapeutic 
effect of a compound. Rather, it is tied to specific host cells transformed with specific genes and grown in the 
presence or absence of a specific type of therapeutic. Moreover, the claim is tied to measuring a therapeutic effect 
on the cells solely by changes in the cells' growth rate."). 
148 Ass'nfor Molecular Pathology, 653 F.3d at 1358 
149 Jacob D. Moore, Note, The Forgotten Victim in the Human Gene Patenting Debate: Pharmaceutical Companies, 
63 FLA. L. REv. 1277, 1287 (suggesting that the viability of Myriad's method claims remains unresolved until a 
Supreme Court opinion in Prometheus). 
150 Jd. at 1287. 
151 Metabolite Laboratories Inc., 548 U.S. at 125. 
152 Jd. 
153 Jd at 138. 
154 ld. at 137. 
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effect up on lower courts. 155 Indeed, the CAFC has rejected or declined to discuss his 
reasoning. 156 
Oral arguments at the Supreme Court for Prometheus seemed to focus on the issue of 
preemption. 157 The Court must consider the line between natural phenomena and patentable 
subject matter: how much "application" must there be to a law of nature to a particular process 
before it is deemed patentable?158 The decision is expected to be close, 159 and more likely to 
provide additional guidance in light of specific circumstances of future cases than a definitive 
legal principle. 
Whatever the outcome of Prometheus is, it will impact the developing doctrine of 
medical diagnostic patents. This is an important and controversial area of law, potentially 
affecting scientific research and patient care as it relates to human genetics.160 However, even if 
the Prometheus decision invalidates the diagnostic method claims at issue in Myriad, other 
laboratories will still be unable to complete diagnostic testing using the BRCAl/2 genes, as the 
patents covering the genes themselves are still valid, and will potentially remain so until the 
Supreme Court hears the Myriad case. 161 
A. Policy Impact 
Although Justice Breyer's LabCorp opinion162 has no binding effect upon lower courts, 
155 Prometheus, 58 I F.3d at I350 n.3; Prometheus, 628 F.3d at I356 n.2. 
156 Prometheus, 58 I F.3d at I350 n.3; Prometheus, 628 F.3d at I356 n.2. 
157 Jonas Anderson, Summary of Mayo v. Prometheus Oral Argument, Patently-0 (Dec. 8, 20 I1, II :25 AM), 
http://www.patentlyo.com/patent/201I/I2/summary-of-mayo-v-prometheus-oral-argument.html. 
158Jd 
159 Denise W. DeFranco, Mayo v. Prometheus Guest Post: The Hot-Button Issues, Patently-0 (Dec. 11,2011, 12:57 
PM), http://www.patentlyo.com/patent/20 11/12/mayo-v-prometheus-guest-post-the-hot-button-issues.html. 
160 Paradise, supra note 15 at 134. 
161 Supreme Court: No Move Yet on Denying Human Gene Patents, Patently-0 (Feb. 21,2012, 12:42 PM), 
http://www.patentlyo.com/patent/2012/02/supreme-court-no-move-yet-on-denying-human-gene-patents.html 
(noting the link between the Prometheus decision and the Myriad case). 
162 Metaholite Lahoratories, Inc., 548lJ.S. 124 (Rreyer, JJ., dissenting). 
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the public policy arguments it discussed have been referenced in the Bilski/63 and Myriad Ii 64 
opinions. Justice Breyer felt it was the Court's provision to "contribute to the important ongoing 
debate, among both specialists and generalists, as to whether the patent system, as currently 
administered and enforced, adequately reflects the 'careful balance' that 'the federal patent laws . 
. . embod[y]. "'165 Breyer recognized that patent restrictions may impact the ability of doctors to 
provide optimal medical care, divert resources from providing medical care in order to avoid 
patent infringement, and increase the cost of health care.166 
Experts have argued that the machine-or-transformation test as put forth in Bilski is not 
well-suited for determining the patentability of the types of diagnostic and genetic testing 
methods that are increasingly used in modem medicine.167 Perhaps the Supreme Court will 
modify the machine-or-transformation test, or disseminate a new test more suited for this type of 
application when it announces its Prometheus decision in the near future. 
The courts have made repeated calls to Congress to address method claim patentability 
through legislation. One of the reasons Justice Breyer felt the Supreme Court should hear the 
Laboratory Corp. case was to "help Congress determine whether legislation is needed."168 
Under the current law, medical practitioners who perform a patented medical or surgical 
procedure on the body will not be held liable for patent infringement.169 This exemption does 
not apply to the use of patented pharmaceuticals or machines, or "biotechnology," though the 
163 Bilski, 130 S. Ct. 3218 (Stevens, JJ., concurring) (referencing the argument that patents may inhibit research by 
increasing costs and discourage the free exchange of information.). 
164 Ass'nfor Molecular Pathology, 653 F.3d at 1380 (Bryson, J., dissenting). 
165 Metabolite Laboratories, Inc., 548 U.S. at 138 (Breyer, JJ., dissenting) (citation omitted). 
166 Metabolite Laboratories, Inc., 548 U.S. at 138 (Breyer, JJ., dissenting). 
167 Brian P. Murphy and Daniel P. Murphy, Bilski's "Machine-or-Transformation" Test Uncertain Prognosis for 
Diagnostic Methods and Personalized Medicine Patents, 20 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 755, 780 
(2010). 
168 Metabolite Laboratories, Inc., 548 U.S. at 138 (Breyer, JJ., dissenting). 
169 35 U.S.C. §287(c) (2011). 
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term ''biotechnology" is not defined in the statute. 170 One option may be for Congress to provide 
a definition of "biotechnology" that includes all patents relating to genetic sequencing. Another 
may be to provide an exemption for diagnostic testing similar to the "medical or surgical 
procedure" currently existing. 
There is evidence that Congress taking note of these issues. On September 16, 2011, 
President Obama signed the Leahy-Smith America Invents Act into law. The Act provides for 
substantial changes to the Patent office, 171 including a provision requiring the Director of the 
USPTO to conduct a study "on effective ways to provide independent, confirming genetic 
diagnostic test activity where gene patents and exclusive licensing for primary genetic diagnostic 
tests exist."172 The directives for the study appear to address many of the concerns raised by the 
plaintiffs in Myriad regarding the impact of genetic diagnostic tests.173 Depending on the 
outcome of this study, future legislation may be enacted directly concerning these tests. If 
Congress feels that patents on "genetic diagnostic tests" are detrimental to patient health, then it 
is up to Congress to pass legislation as an appropriate remedy. 
1. Arguments against the patentability of diagnostic method patents 
Some critics of gene patenting argue that gene patenting is akin to a "land grab" over a 
170 Jd 
171 Press Release, The White House, President Obama Signs America Invents Act, Overhauling the Patent System to 
Stimulate Economic Growth, and Announces New Steps to Help Entrepreneurs Create Jobs (Sept. 16, 2011) 
(http://www.whitehouse.gov/the-press-office/2011/09/16/president-obama-signs-america-invents-act-overhauling-
patent-system-stim). 
172 Leahy-Smith American Invents Act, Pub. L. No. 112-29, § 27, 125 Stat. 284 (2011). 
173 Leahy-Smith American Invents Act; Pub. L. No. 112-29, § 27(b)(1)-(4), 125 Stat. 284 (2011) ("(b) ITEMS 
INCLUDED IN STUDY.--The study shall include an examination ofat least the following: (1) The impact that the 
current lack of independent second opinion testing has had on the ability to provide the highest level of medical care 
to patients and recipients of genetic diagnostic testing, and on inhibiting innovation to existing testing and 
diagnoses. (2) The effect that providing independent second opinion genetic diagnostic testing would have on the 
existing patent and license holders of an exclusive genetic test. (3) The impact that current exclusive licensing and 
patents on genetic testing activity has on the practice of medicine, including but not limited to: the interpretation of 
testing results and performance of testing procedures. (4) The role that cost and insurance coverage have on access 
to and provision of genetic diagnostic tests."). 
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fmite number ofhuman genes.174 Once the entire human genome has been isolated and patented, 
researchers and doctors cannot legally utilize the patented genes without permission (in the form 
of a license) from the patent holder. There is a fear that this will result in high costs on future 
innovators and the underuse of genetic information, which will stunt further research. 175 
A gene patent grant to a biotechnology firm or organization will exclude many ou1ers 
who initially worked on the research leading to the patented test. 176 This policy is often counter 
to the spirit of scientific research.177 The Breast Cancer Linkage Consortium invited 
membership to any researcher willing to share results from his or her studies.178 The Human 
Genome Project openly disseminated the completed gene sequences as soon as they were 
completed. 179 Much of the information used by Myriad was already in the public domain 
because of these kinds of policies. 180 
Several of the plaintiffs represented by the ACLU in the Myriad cases are patients who 
wish to obtairt the BRCAl/2 genetic testing, but are unable to afford the test. 181 Due to the 
exclusionary nature of a patent grant, owners of a patent are able to have almost a monopolistic 
control over the patented subject matter. 182 This concept is especially evident in genetic testing 
"because either there is no way to 'invent around' and put similar products on the market, or 
174 Beyan & Jensen, supra note 6. 
11s Id 
176 Matthijs & Van Ommen, supra note 4 at 323 ("Allowing patent protection to only one organisation tends to 
ignore and disregard in terms of IP rights the contribution of all the other collaborators."). 
177 Id. at 322-323. 
178 Paradise, supra note 15 at 143. 
179 Nat'l Human Genome Research Inst., Nat'l Institutes of Health, 111.e Human Genome Project Completion: 
Frequently Asked Questions, http://www.genome.gov/11006943 (last updated Oct. 30, 2010) ("Every part of the 
genome sequenced by the Human Genome Project was made public immediately - in fact, new data on the genome 
is posted every 24 hours."). 
180 Paradise, supra note 15 at 143; see, e.g., Yoshio Moo, et al., A Strong Candidate for the Breast and Ovarian 
Cancer Susceptibility Gene BRCAJ, Science, 66, Oct. 1994, http://www.sciencemag.org/ 
content/266/5182/66.full.pdf. 
181 Ass'nfor Molecular Pathology, 102 F.Supp.2d at 188-90. 
182 Rebecca S. Eisenberg, Genomic Patents and Product Development Incentives, in HUMAN DNA: LAW AND 
POLICY INTERNATIONAL AND CO:MPARATIVE PERSPECTIVES 373, 374 (Bartha Maria Knoppers ed., 1997). 
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because the diagnostic laboratories lack the power (i.e. a patent portfolio or a suitable substitute 
for the diagnostic test) to negotiate reasonable conditions."183 This has lead to inflation in the 
cost of Myriad's test. 184 
Myriad has likewise impeded patient access to the BRCAl and BRCA2 genetic test, as it 
did not license the test or did not do so at terms acceptable to laboratories.185 Consequently "all 
the tests would have to be performed in its own laboratories in Utah."186 In the United States, 
gene patent holders have successfully deterred other laboratories from performing diagnostic 
tests out of fear of patent infringement lawsuits. 187 A major concern is that doctors and patients 
can no longer obtain second opinions on tests that can carry considerable medical implications, 
such as breast or ovarian cancer.188 
The Myriad patents have also inhibited the development of new tests for BRCAl and 
BRCA2 gene mutations. 189 The quality of the diagnostic test may be impacted by the Myriad 
decision. Different mutations in the BRCAl and BRCA2 genes were found by different 
laboratories using many different testing techniques. 190 "When only a single lab offers a given 
test it is impossible to apply the 'gold standard' of quality assurance--proficiency testing--which 
requires analysis of the same sample by more than one provider."191 Without the collaborative 
effort of many resources, the further progression of diagnostic genetic tests is restricted. 
2. Arguments for Diagnostic Patents 
183 Matthijs & Van Ommen, supra note 4 at 321. 
184 Crichton, supra note 16 ("[A] test for breast cancer that could be done for $1,000 now costs $3,000."). 
185 Matthijs & Van Ommen, supra note 4 at 320. 
186 ld. 
187 Jd. at 321. 
188 Rochelle P. Dreyfuss & James P. Evans, From Bilski Back to Benson: Preemption, Inventing Around, and the 
Case ofGenetic Diagnostics, 63 STAN. L. REv. 1349, 1366 (2011). 
189 Matthijs & Van Ommen, supra note 4 at 321(''[R]egrettably, more than ten years were lost for the development 
of novel technologies applied to BRCA.") 
190 ld at 322. 
191 Dreyfuss & Evans, supra note 188 at 13 66. 
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Proponents of diagnostic method patenting emphasize that the purpose of the U.S. patent 
system is to encourage commercial development of new technologies. 192 The right of exclusion 
afforded a patent owner "is how patents motivate flrms to invest in [research and development], 
an investment that might be unprofitable if free riders were permitted to enter the market for new 
tecili1ologies tt~at prove w1success:ful without having shared i1·1 the initial cost and risk."193 
During the Myriad cases, the ACLU launched a high-profile campaign that attracted 
media attention to a polarizing issue.194 However, some would argue that the ACLU concerns 
are exaggerated: "Generally speaking, published statements criticizing human gene patents tend 
to provide little documented evidence of specific instances where such fears have actually 
manifested themselves."195 While patents do convey a right to exclude, that right is not self-
...,. .;;. 10£ e - ~ ~ - ... ,...... •• "' " • -
enforcmg. J.?V A patent 1s only restrictive when the patent owner successtully brmgs an act1on tor 
patent infringement.197 
Advocates of genetic method patents may find support in the current practices of the 
USPTO. The USPTO allows for certain patent applications to be made "special" which enables 
an application to be examined earlier. 198 Among the criteria for making a patent application 
eligible for "special" status are applications relating to the treatment and cure for HIV I AIDS and 
cancer.
199 One could argue that the diagnostic patents allowed to Myriad Genetics (method of 
192 Eisenberg, supra note 182 at 373. 
193 I d. at 374. 
194 Lauren M. Dune, Note, "Come, Let us Return to Reason": Association of Molecular Pathology v. USPTO, 20 
DePaul J. Art, Tech. & Intell. Prop. L. 473,475 (2010); see also Michael Crichton, Patenting Life, N.Y. TIMES, Feb. 
13,2007, http://www.nytim.es.com/2007/02/13/opinion/13crichton.html ("For years we've been promised the 
coming era of personalized medicine - medicine suited to our particular body makeup. Gene patents destroy that 
dream.") 
195 Holman, Christopher M., The Impact of Human Gene Patents on Innovation and Access: A Survey of Human 
Gene Patent Litigation, 76 UMKC L. REv. 295, 299 (2007). 
196 I d. at 305. 
197 ld 
198 MANuAL OF PATENT EXAMINING PROCEDURE§ 708.02(X) (8th ed. 2001) ("New applications ordinarily are taken 
up for examination in the order of their effective United States filing dates."). 
199 Jd e'In view of the importance of developing treatments and cures for HIV/AIDS and cancer and the desirability 
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seeking potential cancer therapies) are akin to the patent applications afforded special status at 
the USPTO. Determining the genetic cause of serious diseases could lead to breakthroughs in 
treatments. Early detection of genetic predisposition for certain forms of cancer will aid doctors 
in effectively counseling their patients.200 It follows then, that the USPTO fmds value in 
granting patent protection to inventions relating to ameliorating debilitating and serious diseases. 
B. Analysis in Myriad affecting genetic method patents 
Both the ACLU and Myriad Genetics independently petitioned the CAFC for rehearing 
following the decision.201 Both requests were denied, leaving certiorari by the Supreme Court as 
the only option remaining for either party?02 The Supreme Court may vacate the CAFC ruling 
and remand for reconsideration in light of its decision in Prometheus, as it did for Prometheus 
after Bilski. Many believe it is highly likely that the Supreme Court will hear a case involving 
the DNA composition claims, and such a case would invariably impact the related method 
claims?03 The ACLU has filed a petition for a writ of certiorari asking the Court to address 
whether or not human genes are patentable. 204 The Court has deferred deciding whether or not to 
grant the writ of certiorari, perhaps due to the potential influence the pending Prometheus 
opinion will have on Myriad.205 
After the CAFC ruling, Myriad Genetics' claims for isolated DNA and method of 
screening potential cancer therapeutics are still valid, while the method claims of analyzing and 
of prompt disclosure of advances made in these fields, the U.S. Patent and Trademark Office will accord 'special' 
status to patent applications relating to lllV/AIDS and cancer."). 
200 BRCAJ and BRCA2: Cancer Risk and Genetic Testing, NATIONAL CANCER INSTITUTE, 
http://www.cancer.gov/cancertopics/factsheet!risk/brca (last visited Jan. 22, 2012). 
201 Mary Beth Tung, Myriad: Isolated DNA claims from "ball bats in trees," and "kidneys" to "magic 
microscopes.", IPWatchdog (Sept. 25,2011, 8:00AM), http://ipwatchdog.com/2011/09/25/myriad~isolated-dna­
claims/id=19397/. 
202 Jd 
203 Hodes, supra note 21 at 234. 
204 Petition for Writ of Certiorari, Ass 'nfor Molecular Pathology (2011). 
205 Supreme Court: No Move Yet on Denying Human Gene Patents, Patently~O (Feb. 21, 2012, 12:42 PM), 
http://www.patentlyo.com/patent/2012/02/supreme-court-no-move-yet-on-denying-human-gene-patents.html. 
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comparing the isolated DNA sequences are invalid.206 In theory, other hospitals and laboratories 
are now able to offer BRCAl and BRCA2 gene mutation diagnostic testing; however, in order to 
perform such testing, they will be unable to use the isolated BRCAl and BRCA2 genes as those 
are still covered by a valid patent. It is thus necessary for clinicians to deal with Myriad 
Genetics, who has been identified in a report by the Health and Human Services Secret&y's 
Advisory Committee on Genetics, Health, and Society (SACGHS) as raising barriers to patient 
access to breast cancer diagnoses, and failing to deposit new mutations into public databases. 207 
The inability to invent around a patented technology creates problems for both product markets 
and innovation markets. 208 
VII. CONCLUSION 
During the past twenty years great strides have been made regarding the diagnosis and 
treatment of several genetic diseases. Much of this is owed to a great deal of time and resources 
by teams of researchers, several of whom now seek patent protection for their inventions. But 
where is the appropriate line between protecting and encouraging innovation and creating 
barriers for doctors who want to use these tests and treatments to care for patients? The judicial 
response has at times been as dynamic as the controversy surrounding the cases. Myriad has 
shown that, for now, the CAFC is willing to uphold patents related to isolated genetic sequences 
and diagnostic methods utilizing genetic sequences. Within the near future the Supreme Court 
will decide if the CAFC's approach to method patents is correct. Meanwhile, the America 
Invents Act indicates that the legislative branch is starting to pay attention to this very important 
issue. 
206 Federal Circuit: Isolated Human DNA Molecules are Patentable, Patently-0 (July 29,2011, 12:32 PM) 
http://www .patent1yo.com/patent/20 11/07 /federal-circuit-isolated-human-dna-molecules-are-patentable.html. 
207 Dreyfuss & Evans, supra note 188 at 1369. 
208 I d. at 1370. 
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